Baidu
map

Sci Rep:转移前列腺癌中HOXB13同源异型盒基因能够调控有丝分裂蛋白激酶互作网络

2019-07-21 AlexYang MedSci原创

HOXB13是一个同源异型盒转录因子,并且与根治性前列腺切除术后复发有关。虽然HOXB13能够以环境依赖的方式来调控雄激素受体(AR)功能,它在前列腺癌(PC)转移中的关键影响仍旧大部分未知。最近,有研究人员为了鉴定转移性PCs中HOXB13的转录靶标,在人类前列腺肿瘤特异性AR结合位点附近进行了综合的差异化基因表达(DEGs)生物信息学分析。无监督主成分分析(PCA)表明HOXB13靶基因聚焦于

HOXB13是一个同源异型盒转录因子,并且与根治性前列腺切除术后复发有关。虽然HOXB13能够以环境依赖的方式来调控雄激素受体(AR)功能,它在前列腺癌(PC)转移中的关键影响仍旧大部分未知。

最近,有研究人员为了鉴定转移性PCs中HOXB13的转录靶标,在人类前列腺肿瘤特异性AR结合位点附近进行了综合的差异化基因表达(DEGs)生物信息学分析。无监督主成分分析(PCA)表明HOXB13靶基因聚焦于HOTPAM9。HOTPAM9包括了7个有丝分裂基因,并在PCs中过表达;另外,与原发性疾病相比,TRPM8和热激蛋白HSPB8的水平在转移性PCs中显著更低。CIT和HSPB8这2个基因集的整体平衡准确度为98.8%且阈值为0.2347,且能够充分的对转移进行分类。在多个转移性CRPC模型中,HSPB8 mRNA表达水平在HOXB13缺失后显著增加。微管抑制剂秋水仙碱处理或者外源方法使得HSPB8表达的增加能够抑制mCRPC细胞的迁移。

最后,研究人员指出,他们的结果表面了HOXB13能够促进PCs的转移,具体是通过有丝分裂激酶的调控和假定的肿瘤抑制基因的阻断两者协同来实现的。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1981580, encodeId=883419815807a, content=<a href='/topic/show?id=7d1888661a4' target=_blank style='color:#2F92EE;'>#蛋白激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88661, encryptionId=7d1888661a4, topicName=蛋白激酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Oct 25 11:30:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471636, encodeId=c4e014e16361d, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue Jul 23 13:30:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496061, encodeId=ebd6149606179, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Tue Jul 23 13:30:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521451, encodeId=c908152145175, content=<a href='/topic/show?id=f52b605e618' target=_blank style='color:#2F92EE;'>#有丝分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60576, encryptionId=f52b605e618, topicName=有丝分裂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Jul 23 13:30:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040504, encodeId=248b1040504a1, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jul 22 01:30:00 CST 2019, time=2019-07-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1981580, encodeId=883419815807a, content=<a href='/topic/show?id=7d1888661a4' target=_blank style='color:#2F92EE;'>#蛋白激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88661, encryptionId=7d1888661a4, topicName=蛋白激酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Oct 25 11:30:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471636, encodeId=c4e014e16361d, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue Jul 23 13:30:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496061, encodeId=ebd6149606179, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Tue Jul 23 13:30:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521451, encodeId=c908152145175, content=<a href='/topic/show?id=f52b605e618' target=_blank style='color:#2F92EE;'>#有丝分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60576, encryptionId=f52b605e618, topicName=有丝分裂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Jul 23 13:30:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040504, encodeId=248b1040504a1, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jul 22 01:30:00 CST 2019, time=2019-07-22, status=1, ipAttribution=)]
    2019-07-23 ylz8405
  3. [GetPortalCommentsPageByObjectIdResponse(id=1981580, encodeId=883419815807a, content=<a href='/topic/show?id=7d1888661a4' target=_blank style='color:#2F92EE;'>#蛋白激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88661, encryptionId=7d1888661a4, topicName=蛋白激酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Oct 25 11:30:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471636, encodeId=c4e014e16361d, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue Jul 23 13:30:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496061, encodeId=ebd6149606179, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Tue Jul 23 13:30:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521451, encodeId=c908152145175, content=<a href='/topic/show?id=f52b605e618' target=_blank style='color:#2F92EE;'>#有丝分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60576, encryptionId=f52b605e618, topicName=有丝分裂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Jul 23 13:30:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040504, encodeId=248b1040504a1, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jul 22 01:30:00 CST 2019, time=2019-07-22, status=1, ipAttribution=)]
    2019-07-23 redcrab
  4. [GetPortalCommentsPageByObjectIdResponse(id=1981580, encodeId=883419815807a, content=<a href='/topic/show?id=7d1888661a4' target=_blank style='color:#2F92EE;'>#蛋白激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88661, encryptionId=7d1888661a4, topicName=蛋白激酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Oct 25 11:30:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471636, encodeId=c4e014e16361d, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue Jul 23 13:30:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496061, encodeId=ebd6149606179, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Tue Jul 23 13:30:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521451, encodeId=c908152145175, content=<a href='/topic/show?id=f52b605e618' target=_blank style='color:#2F92EE;'>#有丝分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60576, encryptionId=f52b605e618, topicName=有丝分裂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Jul 23 13:30:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040504, encodeId=248b1040504a1, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jul 22 01:30:00 CST 2019, time=2019-07-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1981580, encodeId=883419815807a, content=<a href='/topic/show?id=7d1888661a4' target=_blank style='color:#2F92EE;'>#蛋白激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88661, encryptionId=7d1888661a4, topicName=蛋白激酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Oct 25 11:30:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471636, encodeId=c4e014e16361d, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue Jul 23 13:30:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496061, encodeId=ebd6149606179, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Tue Jul 23 13:30:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521451, encodeId=c908152145175, content=<a href='/topic/show?id=f52b605e618' target=_blank style='color:#2F92EE;'>#有丝分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60576, encryptionId=f52b605e618, topicName=有丝分裂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Jul 23 13:30:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040504, encodeId=248b1040504a1, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jul 22 01:30:00 CST 2019, time=2019-07-22, status=1, ipAttribution=)]
    2019-07-22 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

前列腺癌放射治疗安全共识

前列腺癌放疗的有效性必须建立在安全的前提下。本共识将从条件保障、人员配置、适应证选择、治疗时机、临床操作、相关并发症防治和患者管理等方面,多角度全面介绍接受放疗的前列腺癌患者治疗相关安全性问题。希望通过共识推荐的建议,为国内前列腺癌放疗的安全实施保驾护航。

脂肪细胞膜蛋白:治疗前列腺癌新靶点

前列腺癌是一种泌尿系统恶性肿瘤,对中老年男性造成了巨大的危害。目前,国际公认的研究表明,通过抑制雄性激素的合成,对于治疗前列腺癌已经取得了较好效果。但是,相当一部分患者会逐渐产生抗药性并最终导致癌细胞转移。

Prostate Cancer P D:去势敏感性前列腺癌中醋酸阿比特龙与多烯紫杉醇治疗成本效益分析

一些随机对照试验(RCTs)表明了在雄激素阻断治疗(ADT)中加入醋酸阿比特龙(AA)或者多烯紫杉醇(D)能够改善转移去势敏感性前列腺癌患者(mCSPC)的生存。然而,这些治疗选择的成本效益分析还没有进行完整的比较。最近,有研究人员对香港地区的ADT+AA和ADT+D进行了经济分析。研究人员利用确定性的马尔可夫模型来预测每一种疗法的成本效益情况。模拟与概率敏感性分析整合表明,与ADT单独治疗相比,

Prostate Cancer P D:针对性治疗男性穿刺活检中的细胞周期进程(CCP)评分在预后中的应用分析

在局部前列腺癌男性患者中,准确的风险分层能够帮助指导进行合适的治疗选择。最近,有研究人员在一个大的、汇总分析中评估了针对性治疗的前列腺癌男性中,分子细胞周期进程(CCP)评分和组合细胞周期临床风险(CCR)评分预测10年恶化为转移性疾病风险的能力。汇总分析包括了1062名患者。研究发现,在调整了CAPRA(前列腺癌风险评估)、治疗类型和群体后的多变量分析中,CCP评分与10年转移疾病风险强烈相关(

Eur Urol:复旦肿瘤首次揭示中国高致死性前列腺癌基因图谱

“由于人口基数大和老龄化趋势明显,我国前列腺癌的年死亡人数接近5.2万人,为美国前列腺癌的年死亡人数的两倍。因此,如何降低我国前列腺癌死亡率是迫在眉睫的问题。”前不久,复旦大学附属肿瘤医院泌尿男生殖系统肿瘤多学科综合诊治团队首席专家叶定伟在接受《中国科学报》采访时表示,前列腺癌是我国男性发病率位列第六的恶性肿瘤,也是近年来发病率增长最快的恶性肿瘤。

Baidu
map
Baidu
map
Baidu
map